Taken together, results demonstrate that direct AMPK activators improved cell viability of mitochondrial-defective patient cells, with PT1 showing the most consistent effect across a range of mitochondrial disease etiologies. This evidence concerns the gene PRKAA1 and mitochondrial disease.